A decade later, another MIT retreat explores factors behind slow adoption of technologies touted in the first – and how the barriers could be overcome to deliver higher-quality, more shortage-proof generic drugs.
The vision goes like this: drug manufacturers will build more resilient supply chains and prevent drug shortages by restoring US-based manufacturing, and they will do it by adopting advanced technologies that enable them to achieve higher quality while competing on price against India and China despite higher wages and greater environmental and worker protections in the US.
In support of this vision, the US Food and Drug Administration has worked to facilitate the use of continuous and...
Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.
Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.
Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
